Management Team

Page Header Image

Angelo Moesslang, PhD
Chief Executive Officer

Angelo Moesslang has more than 20 years of executive-level leadership experience and a proven track record as a senior finance leader and executive in the medical device and health care industry. Prior to joining InGeneron, he served as chief financial officer of Fresenius Medical Care North America Holdings, the U.S.-based division of Fresenius Medical Care, a global medical device and health care services group. Earlier roles in his career include CFO for Fresenius Medical Care Europe, Africa, Middle East, and Latin America; vice president for business development for Asia Pacific; and head of investor relations for Fresenius Medical Care. Angelo holds a doctorate in business administration from the University of Hohenheim and a master’s degree in economics from the Ludwig-Maximilians-University Munich.


Ron Stubbers, MBA

Ron Stubbers focuses on the company’s operations, product development, engineering, quality, and regulatory activities. Ron has more than 25 years of experience in operations, engineering, and management of quality and regulatory affairs, product development, and manufacturing engineering. Throughout his career, he has contributed to the development and expansion of companies through organic growth and M&A endeavors.


Fabian Alt, M.Sc.
Chief Financial Officer

Fabian Alt previously served in the Investment Banking Division of Goldman Sachs’s London office. His experience extends across more than 20 completed capital market and M&A transactions, including several equity capital offerings and IPOs. Fabian received his master’s in finance from the London School of Economics and Political Science, earned an honors master’s in technology management from the Technical University of Munich and Ludwig-Maximilians-University Munich, and received a master’s in physics from the Technical University of Munich. In addition, he completed research stays at the Max Planck Institute for Quantum Optics and Massachusetts Institute of Technology.


Glenn Winnier, PhD
Chief Scientific Officer

Glenn Winnier has more than 15 years of experience in scientific leadership and a proven track record in the design of studies that have led to the successful commercialization of novel therapeutics. Previously, he worked for Memorial Hermann, Houston Methodist Research Institute, Opexa Therapeutics, and Lexicon Genetics, where he gained experience in disciplines ranging from the development of intellectual property to regulatory affairs, cGMP manufacturing, and clinical trial management. Glenn received his doctorate in cell biology from Vanderbilt University.